Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 3/20 | 0.45 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6093184 | 0.98 | ALDH1A1 (0.50) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| Hydrazine SCHEMBL27571459 | 0.85 | ALDH1A1 (0.54) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| SCHEMBL134091 | 0.85 | ALDH1A1 (0.59) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| SCHEMBL254364 | 0.85 | ALDH1A1 (0.59) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| SCHEMBL29657201 | 0.85 | ALDH1A1 (0.59) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| Benzene SCHEMBL28132022 | 0.85 | ALDH1A1 (0.59) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| Hydrogen Peroxide SCHEMBL9514730 | 0.85 | ALDH1A1 (0.59) | ALDH1A1ALOX15TDP1GAAKMT2A | |
| SCHEMBL10726252 | 0.83 | IRAK4 (0.43) | ALDH1A1KDM4ESMN1; SMN2ADRA2AADRA2C | |
| SCHEMBL28814411 | 0.83 | IRAK4 (0.43) | ALDH1A1KDM4ESMN1; SMN2ADRA2AADRA2C | |
| SCHEMBL731619 | 0.83 | IRAK4 (0.52) | ALDH1A1GAAMAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299225-B2 | Amidite for synthesizing modified nucleic acid and method for synthesizing modified nucleic acid | FUJITSU LIMITED (JP) | 2012-10-30 | — | — | US | claimed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | FUJITSU LIMITED (JP) | 2009-03-05 | — | — | US | claimed |
| US-20080167459-A1 | Amidite for nucleic acid synthesis and nucleic acid synthesizing method | FUJITSU LIMITED (JP) | 2008-07-10 | — | — | US | claimed |
| US-7053122-B2 | Therapeutic use of aryl amino acid derivatives | PFIZER INC (US) | 2006-05-30 | — | — | US | claimed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1528919-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2005-05-11 | — | — | EP | claimed |
| WO-2005018622-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018621-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043407-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043406-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043345-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | MAW GRAHAM NIGEL (GB) | 2004-07-15 | — | — | US | claimed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| EP-0254009-B1 | A PROCESS FOR PURIFYING DINITROANILINE HERBICIDES | AGAN CHEMICAL MANUFACTURERS LTD. (IL) | 1991-04-17 | — | — | EP | claimed |
| EP-3478725-B1 | MODIFIED CARBOHYDRATES, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF MAKING AND USING THE SAME | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2022-08-10 | — | — | EP | disclosed |
| US-5378728-A | Benzoic acid derivatives as antidiabetic agents | SANDOZ LTD. (CH) | 1995-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167459-A1 | Amidite for nucleic acid synthesis and nucleic acid synthesizing method | GABBR2, RNGTT, BCAT2 | ALDH1A1 1516/4885ALOX15 2974/4885TDP1 764/4885 |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | CNR1, HCRTR1, HTR6 | ALDH1A1 776/4885ALOX15 1746/4885TDP1 399/4885 |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | NSUN2, RNMT, ADAR | ALDH1A1 2737/4885ALOX15 2412/4885TDP1 387/4885 |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | ALDH1A1 1298/4885ALOX15 2819/4885TDP1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.